Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Files An 8-K Other Events
Item 8.01 Other Events

The previously announced partial clinical holds on the clinical trials of selinexor, Karyopharm Therapeutic Inc.’s lead drug candidate, have been lifted by the U.S. Food and Drug Administration Division of Hematology Products (effective March 30, 2017), Division of Oncology Products 1 (effective April 5, 2017) and Division of Oncology Products 2 (effective March 31, 2017).

About Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Company has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. It lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. Its product pipeline includes Verdinexor (KPT-335), an oral SINE compound; KPT-9274, a dual p21-activated kinase 4 (PAK4)/Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, and KPT-350, a compound in development for the treatment of neurological disorders.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Recent Trading Information

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) closed its last trading session down -0.40 at 12.21 with 202,591 shares trading hands.